Free-text search
Content Types
-
AstraZeneca combination shows promise in advanced lung cancer
AstraZeneca and China's Hutchmed have reported positive phase III results for a combination of their cancer drugs Tagrisso and Orpathys in advanced lung cancer.
-
Chinese approval for Leqembi auto-injector
BioArctic’s partner Eisai has received approval in China for the subcutaneous auto-injector formulation of Leqembi as an initial treatment for early Alzheimer’s...
-
A growing industry in Denmark: “One new life science company a week”
The life science sector in eastern Denmark continues to grow in the number of employees, as well as the number of companies. An emerging problem is the shortage...
-
ZEISS debuts DORC EVA NEXUS for cataract surgery at ESCRS
Now spanning ZEISS Retina and Cataract Workflows, the EVA NEXUS™ ophthalmic surgical system from ZEISS comes in a cataract-only configuration, bringing a tailor...
-
Rarity Bioscience targets hidden disease signal with new test
Rarity Bioscience has a lot going on. The Uppsala-based company is launching an ultra-sensitive blood test for systemic mastocytosis while preparing to move int...
-
Egetis lands FDA approval: “Biggest milestone in the company’s history”
Swedish Egetis Therapeutics has secured FDA approval for its rare disease drug Emcitate, clearing the way for a US launch within weeks. “We are transitioning fr...
-
Novartis hit by another major setback – shares plunge
Novartis has suffered another major pipeline setback. A key drug candidate acquired through its $12bn takeover of Avidity has failed in phase III, sending the c...
-
“There’s no magic wand” – The urgent need for new treatments
One in ten women with recurrent yeast infections develops a stubborn, hard-to-treat condition for which no effective therapies currently exist. At Danderyd Hosp...
-
Potions, Placebos and Perilous Practices – Macabre Mistakes in the History of Medicine
Tobacco for cancer, heroin for coughs, mercury for teething babies. Humanity’s path towards today’s evidence‑based medicine has been lined with strange misjudge...
-
Swedish‑developed CT scanner cleared in Europe: “Very exciting”
GE Healthcare’s photon‑counting computed tomography (PCCT) system, Photonova Spectra, has now received CE Mark, enabling the Swedish‑developed technology to be ...
-
Danish health minister: Europe must act on China
Danish politicians and medtech industry representatives are calling for closer cooperation between hospitals and companies to boost innovation. Danish Health Mi...
-
Swedish-Danish meeting at Medicon Village: “One of the most important life science congresses”
For the eleventh year, The Future of Swedish and Danish Life Science was held on Wednesday, and the event continues to function as a connecting link between the...
-
Stockholm aims at becoming one of the world’s top life science regions
Regional Chair for Finance, Irene Svenonius (M), believes that Stockholm can realise the goal of becoming one of the world’s top 5 regions in life science by 2025. One step on the way to achieve this is by hosting a world-leading congress in medtech....
-
Gothenburg-based Anyo Labs gains ground in the AI race
In a fifty-square-metre space in Gothenburg sits a company aiming to secure its place on one of the world's hottest technological stages: AI-driven drug develop...
-
The vaccine has saved 94 million lives – but measles is spreading again
A disease we once believed belonged to the past is now resurging in both Europe and the United States. In Sweden, 24 cases of the disease have so far been repor...
-
CF drug flops in phase II — shares collapse
A new experimental treatment for cystic fibrosis failed unexpectedly in phase II — and Sionna Therapeutics’ share price dropped by more than 90 percent.
-
Hacker group claims Chinese bid for stolen Novo data
Earlier this year, Novo Nordisk was hit by a high‑profile data breach in which a large amount of sensitive information was stolen. Now a hacker group claims tha...
-
Canada approves leqembi as global alzheimer’s drug race heats up
Leqembi has secured approval in Canada, further consolidating its global lead among disease-modifying Alzheimer’s therapies. The antibody is now authorized in 1...
-
Lantheus challenges Eli Lilly with FDA-approved Alzheimer’s tracer
Eli Lilly has until now had the US market for tau PET imaging in Alzheimer’s disease to itself. The pharmaceutical giant is now facing competition after the FDA...
-
Cyberattacks surge – the medtech companies hit this year
Healthcare has long been a target for cyberattacks, resulting in operational disruption and the theft of sensitive data. This year, however, growing numbers of ...
-
Licensing breakthroughs propel AlzeCure to first‑ever profit
With two out‑licensed Alzheimer projects now in place, Sweden’s AlzeCure Pharma is reporting a profit for the first time since the company was founded in 2016. ...
-
XVIVO’s heart technology receives CE certificates
XVIVO has been granted CE certification for its preservation and transport system for donor hearts — allowing it to be used clinically in Europe. ”This is a pro...
-
AstraZeneca scraps late‑stage study – and reports dual successes in lung cancer
AstraZeneca is discontinuing a global Phase III trial that has been evaluating the antibody volrustimig for non‑small cell lung cancer after the chances of succ...
-
Phase III win for LSD‑based anxiety drug
An LSD‑based drug candidate for anxiety disorders is reported to show strong results in late‑stage clinical testing.
BREAKING